Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 1
Submit an article Journal homepage
782
Views
17
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

Artur JurczyszynHematology Department, Jagiellonian University Medical College, Cracow, Poland; Correspondence[email protected]
,
Jorge J. CastilloDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; ORCID Iconhttp://orcid.org/0000-0001-9490-7532
ORCID Icon,
Irit AviviTel Aviv Medical Center, Tel Aviv, Israel;
,
Jacek CzepielDepartment of Infectious and Tropical Diseases, Jagiellonian University Medical College, Cracow, Poland;
,
Julio DavilaHospital Universitario de Salamanca, Salamanca, Spain;
,
Ravi VijWashington University School of Medicine, Saint Louis, MO, USA;
,
Mark A. FialaWashington University School of Medicine, Saint Louis, MO, USA;
,
Alessandro GozzettiLe Scotte Hospital, Siena, Italy;
,
Norbert GrząśkoDepartment of Hematology, St John’s Cancer Center, Lublin, Poland; ;Department of Experimental Hematology, Medical University of Lublin, Lublin, Poland;
,
Vibor MilunovicDivision of Hematology, Clinical Hospital Merkur, Zagreb, Croatia;
,
Iwona HusDepartment of Haematology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland;
,
Krzysztof MądryDepartment of Hematology, Oncology and Internal Medicine, Warsaw Medical University, Warsaw, Poland;
,
Anna Waszczuk-GajdaDepartment of Hematology, Oncology and Internal Medicine, Warsaw Medical University, Warsaw, Poland; ORCID Iconhttp://orcid.org/0000-0001-5626-1750
ORCID Icon,
Lidia Usnarska-ZubkiewiczDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland;
,
Jakub DębskiDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland;
,
Erden AtillaHematology Department and Bone Marrow Transplantation Unit, Ankara University Medical School, Ankara, Turkey;
,
Meral BeksacHematology Department and Bone Marrow Transplantation Unit, Ankara University Medical School, Ankara, Turkey;
,
Giuseppe MeleOspedale A. Perrino, Haematology, Brindisi, Italy;
,
Waldemar SawickiDepartment of Internal Medicine and Hematology, Military Institute of Medicine, Warsaw, Poland;
,
David JayabalanWeill Cornell Medical College, New York, NY, USA;
,
Grzegorz CharlińskiDepartment of Hematology, Nicolaus Copernicus Hospital, Torun, Poland;
,
Agoston Gyula SzaboDepartment of Medicine, Section of Hematology, Vejle, Denmark;
,
Roman HajekFaculty of Medicine, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic;
,
Michel DelforgeDepartment of Hematology, UZ Leuven, Leuven, Belgium;
,
Agnieszka KopaczTeaching Hospital No. 1, Rzeszów, Poland;
,
Dorotea FantlSeccion Hematologia Adultos, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;
,
Anders WaageNorwegian University of Science and Technology, St. Olav’s Hospital, Trondheim, Norway;
,
Edvan CrusoeHospital Universitario Professor Edgar Santos, Salvador, Brazil;
,
Vania HungriaHospital Universitario Professor Edgar Santos, Salvador, Brazil;
,
Paul RichardsonDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;
,
Jacob LaubachDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;
,
Thomas Guerrero-GarciaDivision of Hematology and Oncology, Dana-Farber Cancer Institute at St. Elizabeth’s Medical Center, Brighton, MA, USA;
,
Jieqi LiuRutgers New Jersey Medical School, Newark, NJ, USA;
&
David H. VesoleJohn Theurer Cancer Center, Myeloma Division, Hackensack University Medical Center, Hackensack, NJ, USA
 show all
Pages 118-123 | Received 08 Jan 2018, Accepted 22 Apr 2018, Published online: 02 Jul 2018

References

  • Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.
  • Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987;83:1062–1068.
  • Gluziński A, Reichenstein M. Myeloma i leukaemia lymphatica (plasmocellularis). Pol Arch Nauk Biochem Lek. 1907;3:181–211.
  • Jimenez-Zepeda VH, Dominguez VJ. Plasma cell leukemia: a rare condition. Ann Hematol. 2006;85:263–267.
  • Jurczyszyn A, Zawirska D, Skotnicki AB. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. Przegl Lek. 211;68:320–325.
  • International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757.
  • Cha CH, Park CJ, Huh JR, et al. Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol. 2007;118:178–182.
  • Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer. 2007;109:2285–2290.
  • Gozzetti A, Musto P, Defina M, et al. Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia. Br J Haematol. 2012;157:497–498.
  • Katodritou E, Terpos E, Kelaidi C, et al. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek Myeloma Study Group. Am J Hematol. 2014;89:145–150.
  • Jimenez-Zepeda VH, Reece DE, Trudel S, et al. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia. Leuk Lymphoma. 2015;56:232–235.
  • Dos Santos VM, Melim SP, de Faria PS, et al. Multiple myeloma and secondary plasma cell leukemia. Rom J Morphol Embryol. 2016;57:837–839.
  • Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473.
  • Drake MB, Iacobelli S, van Biezen A, et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica. 2010;95:804–809.
  • Mahindra A, Kalaycio ME, Vela-Ojeda J, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012;26:1091–1097.
  • Dimopoulos MA, Palumbo A, Delasalle KB, et al. Primary plasma cell leukaemia. Br J Haematol. 1994;88:754–759.
  • Lebovic D, Zhang L, Alsina M, et al. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011;11:507–511.
  • Usmani SZ, Nair B, Qu P, et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with total therapy protocols. Leukemia. 2012;26:2398–2405.
  • Jung SH, Lee JJ, Kim K, et al. The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget. 2017;8:18535.
  • D'Arena G, Valentini CG, Pietrantuono G, et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol. 2012;23:1499–1502.
  • Musto P, Simeon V, Martorelli MC, et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014;28:222–225.
  • Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood. 2001;97:822–825.
  • Pagano L, Valentini CG, De Stefano V, et al. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol. 2011;22:1628–1635.
  • Royer B, Minvielle S, Diouf M, et al. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du Myelome. J Clin Oncol. 2016;34:2125–2132.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.